Drug Profile

Ramucirumab biosimilar - Klus Pharma

Alternative Names: A-168

Latest Information Update: 12 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Klus Pharma
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Discontinued Cancer

Most Recent Events

12 Nov 2025 Discontinued - Phase-I for Cancer in USA (Parenteral) before November 2025 (KLUS Pharma pipeline, November 2025)
31 Mar 2025 Ramucirumab biosimilar is still in phase I development in Cancer in USA (Parenteral) (Klus Pharma pipeline, March 2025)
28 Sep 2024 No recent reports of development identified for phase-I development in Cancer in USA (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com